Stark Law, formally the Physician Self-Referral Law (42 U.S.C. 1395nn), prohibits a physician from referring Medicare or Medicaid patients for designated health services to an entity with which the physician or an immediate family member has a financial relationship, unless a specific statutory or regulatory exception applies. The law is strict liability: intent is not an element, and the prohibition applies regardless of whether the financial relationship actually influenced the referral. In a healthcare acquisition context, Stark is relevant because the target practice almost certainly has financial relationships with hospitals, labs, imaging centers, and other providers that must be structured to fit within an applicable exception. Buyers acquiring physician practices must conduct a comprehensive Stark analysis of all existing financial relationships. This blog content is educational and does not constitute legal advice. Transactions require review by qualified healthcare M&A counsel.

Stark Law and Anti-Kickback in Healthcare M&A: What Buyers Must Assess

Q: How is Stark different from Anti-Kickback?

Stark Law and the Anti-Kickback Statute (AKS) are distinct statutes that overlap significantly in healthcare M&A. Stark is a civil strict-liability statute focused specifically on physician self-referrals for designated health services billed to Medicare and Medicaid. There is no intent element: if a financial relationship exists and no exception applies, the referral is prohibited and the resulting claims are not payable. AKS is a criminal statute that prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or reward referrals of items or services covered by federal healthcare programs. AKS has an intent element and a broader reach: it applies to all providers and suppliers, not just physicians, and covers services beyond designated health services. In practice, a transaction that implicates Stark will almost always warrant an AKS analysis as well, but the two analyses are conducted separately because the exceptions and safe harbors differ.

Q: Does Stark apply to private-pay only practices?

Stark Law applies only to Medicare and Medicaid reimbursement. A physician practice that treats exclusively private-pay patients and has no Medicare or Medicaid billing is not subject to Stark's prohibitions. However, very few physician practices in the United States operate entirely outside Medicare and Medicaid. Even a primarily cash-pay practice may have a small number of Medicare or Medicaid patients, which triggers Stark's application. In a healthcare acquisition, buyers should confirm whether the target has any Medicare or Medicaid billing before concluding that Stark does not apply. Where billing exists, the analysis requires a full review of the practice's financial relationships, regardless of what percentage of revenue comes from federal programs. AKS may also have implications beyond Medicare and Medicaid to the extent other federal healthcare programs are implicated.

Q: What is an FMV compensation opinion?

A fair market value (FMV) compensation opinion is an independent assessment by a qualified valuation expert of the commercially reasonable compensation level for physician services or a physician financial relationship. Under the Stark exceptions and AKS safe harbors that rely on FMV, compensation arrangements between physicians and entities to which they refer must be set at FMV and not take into account the volume or value of referrals. In healthcare M&A, FMV opinions are relevant both for pre-close diligence (evaluating whether existing physician compensation arrangements were structured at FMV) and for post-close integration (establishing new compensation structures for physicians joining the acquirer's organization). A credible FMV opinion is typically obtained from an independent healthcare valuation firm that specializes in physician compensation analysis. Buyers should understand that FMV methodologies are fact-specific and subject to different interpretations, making qualified counsel and independent valuation essential.

Q: What is the isolated transaction safe harbor?

The isolated transaction safe harbor under the Anti-Kickback Statute is a safe harbor designed to protect certain one-time arm's length transactions, such as the sale of a physician practice, from AKS scrutiny. To meet the safe harbor, the transaction must involve a single discrete transaction, the amount paid must be consistent with fair market value in an arm's length transaction, and the amount paid must not be determined in a way that takes into account the volume or value of referrals. The isolated transaction safe harbor is relevant in practice acquisitions where a physician is selling the practice to a hospital, health system, or other entity to which the physician previously referred patients. Qualifying for a safe harbor provides a level of protection, but safe harbors under AKS are voluntary: transactions that do not fit a safe harbor are not automatically illegal and must be evaluated under the full intent-based AKS standard. This content is educational only. Structure analysis requires qualified healthcare counsel.

Q: Can I inherit a Stark violation from the seller?

In a stock purchase, the buyer acquires the legal entity, including its historical liabilities. If the target practice operated under physician compensation arrangements that violated Stark Law, and those violations generated claims submitted to Medicare or Medicaid that were not properly disclosed and repaid, the buyer in a stock acquisition inherits that liability. In an asset purchase, the buyer generally does not inherit the seller's historical Stark liabilities unless they are expressly assumed. However, even in an asset purchase, a buyer who is aware of a Stark issue and proceeds without addressing it faces post-close regulatory risk if the issue surfaces in a government investigation. Regardless of deal structure, buyers should conduct sufficient Stark diligence to identify potential violations and negotiate appropriate representations, warranties, and indemnification coverage. Where violations are identified, pre-close self-disclosure may be appropriate, but that determination requires healthcare compliance counsel.

Q: What is a corporate integrity agreement?

A corporate integrity agreement (CIA) is a formal compliance agreement between a healthcare provider and the Office of Inspector General (OIG) of the Department of Health and Human Services, typically entered as part of the resolution of a healthcare fraud or abuse matter. CIAs impose specific compliance obligations on the provider, often including independent review organization audits, compliance program requirements, reporting obligations, and exclusion risk provisions. In healthcare M&A, the existence of a CIA at the target is a material diligence finding. A CIA imposes ongoing obligations that survive a change of ownership and can affect operations post-close. Buyers in stock acquisitions assume the CIA obligations along with the entity. Even in asset purchases, buyers should understand the CIA's scope and confirm whether it affects any assets or operations being acquired. CIAs are public documents listed on the OIG website.

Q: What reps should a buyer require on fraud and abuse?

Buyers in healthcare M&A should require the seller to represent and warrant that the target practice has complied in all material respects with Stark Law and the Anti-Kickback Statute throughout the applicable lookback period. Beyond the general compliance representation, buyers typically require specific reps covering: that all physician compensation arrangements have been documented in written agreements that meet applicable Stark exceptions and AKS safe harbors; that compensation has been set at fair market value without taking into account the volume or value of referrals; that the practice has not received a civil investigative demand, subpoena, or government inquiry relating to fraud or abuse; that no officer, director, or employee has been excluded from federal healthcare programs; and that the practice has no obligation under a CIA, deferred prosecution agreement, or settlement agreement. The scope and survival period of these reps, along with the indemnification structure backing them, are critical negotiating points. This content is educational and not legal advice.

Healthcare acquisitions involve a layer of federal regulatory analysis that has no counterpart in most other industries. Stark Law and the Anti-Kickback Statute create a compliance framework around physician financial relationships and referral arrangements that must be understood before any physician practice or healthcare entity changes hands. The consequences of getting this analysis wrong are not commercial: they are regulatory, reaching into government program repayment obligations, potential False Claims Act exposure, and in the most serious cases, criminal liability.

A buyer who acquires a physician practice without analyzing the target's existing financial relationships for Stark and AKS compliance can inherit a set of obligations, defenses, and potential repayment obligations that were never priced into the deal. The work is done in diligence, not after close.

This guide is part of the Healthcare Practice Acquisition Guide cluster. It covers the structure of both statutes, the exceptions and safe harbors relevant to M&A, the diligence process for identifying compliance gaps, and the transactional protections buyers require at close. For the HIPAA and PHI dimension of healthcare acquisitions, see the companion article on HIPAA compliance in healthcare M&A.

Buyers evaluating the broader transaction framework for a healthcare acquisition should also review the M&A due diligence guide and the asset purchase versus stock purchase guide. Deal structure has direct implications for how Stark and AKS liability is allocated between buyer and seller.

Request Engagement Assessment

The Purpose of Stark Law in Physician Referral Relationships

Stark Law was enacted based on a straightforward concern: when a physician refers patients to a facility in which the physician has a financial interest, the referral decision may be influenced by the economic benefit to the physician rather than the patient's medical needs. Congress designed the statute to remove that conflict from the Medicare and Medicaid payment systems.

The core prohibition is that a physician may not refer a Medicare or Medicaid patient for a "designated health service" to an entity with which the physician or an immediate family member has a "financial relationship," unless a specific exception applies. Designated health services include clinical laboratory services, physical therapy, radiology services, radiation therapy, durable medical equipment, home health services, outpatient prescription drugs, and a number of other categories that cover the majority of ancillary services associated with primary care and specialty practices.

Financial relationships under Stark are broadly defined to include ownership and investment interests as well as compensation arrangements. Any payment from an entity to a physician, or from a physician to an entity, can constitute a compensation arrangement that triggers Stark analysis. This breadth means that employment agreements, medical director contracts, space and equipment leases, on-call arrangements, and any other financial arrangement between a physician and an entity to which the physician refers are all potentially subject to Stark.

Stark Law: Key Structural Elements

Strict liability: A Stark violation does not require any showing of intent or knowledge. If a financial relationship exists and no exception applies, the prohibition is triggered regardless of whether the financial relationship influenced the referral.

Payment prohibition: Claims submitted to Medicare or Medicaid for designated health services provided pursuant to a prohibited referral are not payable. The entity must refund any amounts received, and continued submission of claims can trigger False Claims Act liability.

Civil monetary penalties: The government can impose civil monetary penalties on entities that present claims for services resulting from prohibited referrals, with per-claim penalties that can accumulate significantly across a practice's billing history.

Exclusion risk: Entities and physicians involved in Stark violations can face exclusion from Medicare and Medicaid participation, which for a healthcare practice is effectively a business-ending consequence.

How Stark Law Differs from the Anti-Kickback Statute

Stark and AKS are frequently discussed together because they cover overlapping conduct, but they are distinct statutes with different structures, different scope, and different enforcement mechanisms. Understanding the differences matters in M&A diligence because a transaction may satisfy a Stark exception while still presenting AKS risk, or vice versa.

The key structural differences are: Stark is civil and strict liability; AKS is criminal and requires knowing and willful conduct. Stark applies only to physicians and designated health services; AKS applies to any provider, supplier, or individual and covers all items and services reimbursable by any federal healthcare program. Stark is exception-based: compliance requires fitting within a specific exception. AKS is intent-based: conduct that does not fit a safe harbor is not automatically illegal but must be evaluated under the full statutory standard.

False Claims Act exposure: Both Stark and AKS violations can give rise to False Claims Act (FCA) liability when claims are submitted to Medicare or Medicaid in connection with a violation. Under the FCA, a claim submitted as a result of an AKS violation is deemed a false or fraudulent claim, regardless of whether the underlying service was medically necessary. FCA liability includes per-claim civil penalties and treble damages. In a stock acquisition, the buyer inherits the target's FCA exposure for pre-close conduct.

Qui tam relators: The FCA includes a qui tam provision allowing private individuals with knowledge of fraud against the government to file suit on the government's behalf. Disgruntled former employees, competitors, or insiders who are aware of a target's Stark or AKS compliance issues can file qui tam actions after close. This is a category of post-close liability risk that is difficult to fully diligence because the existence of a pending qui tam complaint is typically sealed during the government's investigation period.

Coordination of diligence: In practice, a healthcare M&A diligence process reviews compensation arrangements against both Stark and AKS simultaneously. Where an arrangement fits a Stark exception but does not meet an AKS safe harbor, the arrangement is analyzed under the AKS intent standard: does the arrangement have a legitimate business purpose, is the compensation at FMV, and is there no evidence that the arrangement was designed to induce referrals? Qualified healthcare counsel conducts both analyses as an integrated review.

Stark Exceptions Relevant to Physician Practice Acquisitions

The Stark statute and CMS regulations contain a detailed list of exceptions that permit physician financial relationships that would otherwise be prohibited. Each exception has specific structural requirements that must be satisfied in full. Partial compliance with an exception does not provide protection: if a compensation arrangement meets all but one requirement of an exception, the arrangement is not protected and the resulting referrals are prohibited.

The exceptions most frequently relevant in physician practice acquisitions include the employment exception, the personal services exception (including the fair market value compensation exception added by the 2021 Stark Final Rule), the group practice exception for physician-owned practices, the isolated transaction exception, and the ownership and investment interest exceptions for certain permitted referrals within integrated systems.

Common Stark Exceptions in Healthcare Acquisitions

Employment exception: Protects compensation paid by an employer to a physician-employee if the compensation is for identifiable services, is consistent with fair market value, and is not determined in any manner that takes into account the volume or value of referrals. Post-close physician employment arrangements must be structured to meet this exception.

Personal services exception: Protects compensation under an arrangement for legitimate personal services (such as medical director or on-call agreements) if the arrangement is set out in a signed written agreement, covers all services to be provided, compensates at FMV, and is not determined by referral volume or value. Written documentation requirements are strictly enforced.

Fair market value compensation exception: Added by the 2021 Stark Final Rule, this exception protects compensation arrangements that meet a set of requirements including FMV compensation, a written agreement, and commercially reasonable services, without the hour and set-in-advance requirements of the personal services exception. This exception expands flexibility for certain compensation structures.

Isolated transaction exception: Protects a one-time isolated financial transaction, such as the sale of a medical practice, if the amount is consistent with FMV in an arm's length transaction and is not determined in any manner that takes into account the volume or value of referrals. This exception is discussed in more detail in its own section below.

The 2021 Stark Final Rule made a number of significant changes to the exception framework, including adding new value-based care exceptions and revising requirements for several existing exceptions. Buyers reviewing pre-2021 compensation arrangements should assess whether those arrangements were structured under the prior rule requirements and whether any analysis is needed under the revised framework. Healthcare counsel familiar with the current regulatory landscape should conduct this assessment.

Safe Harbors Under the Anti-Kickback Statute

The Anti-Kickback Statute's implementing regulations establish safe harbors that describe specific types of arrangements which, if structured to meet all safe harbor requirements, are protected from AKS scrutiny. Safe harbor protection is voluntary: a transaction that does not fit a safe harbor is not automatically illegal. However, fitting within a safe harbor provides a high level of assurance that the arrangement will not be challenged.

The safe harbors most relevant to healthcare M&A and physician practice acquisitions include the employment safe harbor, the personal services and management contracts safe harbor, the isolated transaction safe harbor, the investment interests safe harbor for certain group practices, and the value-based arrangements safe harbor added by the 2020 AKS Final Rule.

Safe harbor requirements are all-or-nothing: Like Stark exceptions, AKS safe harbors require full satisfaction of all conditions. An arrangement that meets nine out of ten safe harbor requirements does not qualify for protection. In diligence, counsel reviews existing arrangements against applicable safe harbor criteria and identifies any gaps. Where a safe harbor is not met, the arrangement is evaluated under the intent-based AKS standard. Counsel determines whether the arrangement has a legitimate business purpose, compensation is at FMV, and there is no evidence of intent to induce or reward referrals.

The 2020 AKS Final Rule modernized the safe harbor framework to address value-based care arrangements, care coordination, and certain cybersecurity and technology assistance arrangements. These updates are relevant for integrated health system acquisitions and arrangements involving health information technology. Buyers acquiring practices with complex care coordination or value-based contracting arrangements should review those arrangements under the current safe harbor framework.

Isolated Transaction Safe Harbor at Acquisition

The isolated transaction safe harbor under AKS and the isolated transaction exception under Stark are the primary provisions that protect the sale of a physician practice from fraud and abuse scrutiny. Their requirements are similar but not identical, and both must be analyzed when a physician is selling a practice to an entity to which they refer patients.

Under the AKS isolated transaction safe harbor, the transaction must involve a single discrete transaction. It cannot involve multiple payments over time, and it cannot include ongoing compensation arrangements (such as employment of the selling physician post-close at above-market rates) that effectively spread the acquisition payment over future periods in a way that could be viewed as additional consideration for referrals.

FMV at acquisition: The purchase price must be consistent with fair market value in an arm's length transaction. A purchase price that exceeds FMV can be interpreted as additional remuneration for referrals, particularly if the buyer is a hospital or health system that benefits economically from the acquired physicians' referrals. Independent valuation of the practice is strongly advisable where the acquirer is a referral recipient.

Post-close employment analysis: The isolated transaction safe harbor covers the sale transaction itself. Post-close employment of the selling physician by the buyer is a separate arrangement that must meet its own safe harbor or exception. If the post-close employment compensation is above FMV, the excess may be viewed as additional acquisition consideration that potentially implicates AKS even if the isolated transaction safe harbor otherwise applies. Buyers should ensure that post-close physician employment is structured independently at FMV from the outset.

Earnout structures: Practice acquisitions that include earnouts or contingent consideration tied to future patient volume, referrals, or revenue from referral sources require careful review. An earnout that effectively pays the selling physician more if future referrals are maintained at pre-close levels raises both AKS safe harbor and Stark exception concerns and generally cannot qualify for the isolated transaction protection. Earnout structures in physician practice acquisitions require specific healthcare compliance analysis.

Fair Market Value and Commercially Reasonable Compensation

Fair market value (FMV) and commercial reasonableness are threshold requirements for most Stark exceptions and many AKS safe harbors that involve physician compensation. These concepts are distinct under the regulatory framework, and both must be satisfied independently.

FMV under Stark is defined as the value in arm's length transactions consistent with general market value. In the context of physician compensation, FMV refers to the compensation that a comparable physician would receive for the same services in the same market, determined without reference to the volume or value of any referrals between the parties. Compensation surveys from major healthcare valuation consultants are commonly used as benchmarks, but surveys are a reference point, not a safe harbor. Compensation that exceeds survey benchmarks requires additional justification.

Commercial reasonableness is a separate inquiry: whether the arrangement makes sense from a legitimate business perspective, even if no referrals were made between the parties. A hospital that pays a physician a medical director fee for services that have no legitimate operational function, or at a level that cannot be justified by the services provided, fails the commercial reasonableness standard regardless of what FMV surveys show. Both FMV and commercial reasonableness must be assessed and documented.

FMV Diligence in Healthcare Acquisitions: Key Considerations

✓Review all existing physician compensation arrangements for written documentation establishing FMV basis
✓Assess whether compensation levels are supported by independent FMV opinions from qualified healthcare valuators
✓Identify any compensation arrangements where the level or structure may correlate with referral patterns
✓Review medical director and administrative compensation arrangements for commercial reasonableness documentation
✓Evaluate whether post-close compensation structures are in place and meet FMV and commercial reasonableness standards independently of the acquisition consideration
✓Confirm that any FMV opinions in the seller's files are current, cover the relevant compensation components, and were prepared by qualified independent valuators

Group Practice Exception and Its Requirements

The Stark Law contains a group practice exception that permits physician members of a qualifying "group practice" to refer patients within the group for designated health services without violating the self-referral prohibition. The group practice exception is foundational to the operation of multi-physician specialty practices and medical groups. Whether a target practice qualifies as a group practice under the Stark regulatory definition is a critical threshold determination in physician practice acquisitions.

To qualify as a group practice under Stark, a physician organization must satisfy a specific set of structural and operational requirements. These requirements address the organization of the practice, how physician compensation is determined, how overhead and income are pooled, and how profits from in-office ancillary services (which are permitted under a separate Stark exception for qualifying group practices) are distributed. The requirements are detailed and technical, and practices that believe they qualify as group practices should have that conclusion verified by healthcare counsel as part of the diligence process.

In-office ancillary services exception: A separate and important Stark exception allows a group practice to provide certain ancillary services (such as imaging, laboratory, and physical therapy) within the group practice without triggering the self-referral prohibition, provided the services are supervised by a physician member of the group and billed under the group's Medicare billing number. This exception is often central to a specialty practice's revenue model. Buyers should confirm that the target's in-office ancillary services operation meets all requirements of this exception, including the supervision and billing requirements that are enforced in audits and investigations.

Integrated Healthcare System Acquisitions Under Stark

When a hospital, health system, or larger healthcare entity acquires a physician practice, the resulting financial relationships between the acquired physicians and the acquiring system must be structured to satisfy applicable Stark exceptions going forward. The acquisition itself may trigger the isolated transaction exception, but the ongoing employment and compensation arrangements created at close must independently satisfy their own exceptions.

Integrated system acquisitions are particularly complex from a Stark standpoint because the acquiring entity is typically a hospital or health system that benefits from the acquired physicians' referrals. The economic benefit to the buyer from the referral stream is significant, which makes the FMV and commercial reasonableness analysis of post-close compensation more scrutinized. CMS and OIG have historically focused enforcement attention on hospital-physician compensation arrangements where compensation levels are above market and the physician directs substantial referral volume to the hospital.

Buyers that are hospitals or health systems should also consider the Stark implications for the integrated system's existing physician relationships. Adding a new practice to the system's network may create new financial relationships with existing hospital-employed physicians or affect the analysis of existing arrangements. Healthcare systems that are acquiring practices as a growth strategy should have a systematic Stark compliance infrastructure that covers both the acquisition transaction and the ongoing management of physician financial relationships post-close.

Conducting Stark and AKS Diligence on a Healthcare Acquisition?

Alex Lubyansky works with healthcare buyers on physician practice acquisitions, fraud and abuse compliance diligence, and post-close integration structuring. Submit your transaction details for an engagement assessment.

Diligence Red Flags for Stark and AKS Violations

Healthcare M&A diligence for Stark and AKS issues requires reviewing a range of documents and patterns that may indicate compliance problems. The following are common red flags that warrant deeper investigation and may require healthcare compliance counsel to assess.

Undocumented or oral arrangements: Stark exceptions and AKS safe harbors generally require written arrangements. Compensation arrangements that are described in the data room as oral understandings, undocumented practices, or "based on course of dealing" are red flags. Unwritten physician compensation arrangements cannot qualify for most Stark exceptions.

Compensation significantly above market benchmarks: Physician compensation that is at the 90th percentile or above for comparable specialties and markets warrants review of the underlying FMV justification. While high compensation is not inherently a violation, compensation that exceeds survey benchmarks without documented justification is a pattern that regulators scrutinize.

Compensation correlated with referral patterns: Any arrangement where physician compensation or bonuses track with the volume of referrals to a specific facility or entity is a structural red flag. Productivity bonuses that are calculated based on services provided through a referral recipient rather than services personally performed by the physician are a particularly acute issue.

Medical director agreements with minimal documentation: Medical director fees paid to physicians who refer significant volume to the hospital or practice, where the scope of actual services rendered is not well-documented, are a common AKS diligence concern. The fee must reflect actual services at FMV.

Prior government inquiries: Any civil investigative demand, government audit, Zone Program Integrity Contractor review, or inquiry from a Medicare Administrative Contractor that the target has received is a significant diligence finding. Buyers should request complete disclosure of any government contact regarding billing or compliance.

Expired written agreements: Stark exceptions generally require that compensation arrangements be set out in a signed written agreement. An employment or personal services agreement that has lapsed or expired without renewal means the arrangement may not have been protected during the period of lapse. Identifying expired agreements and assessing whether payments continued during the lapse period is a standard diligence task.

Self-Disclosure and CIA Implications for Buyers

When a Stark or AKS compliance issue is identified in diligence, the question of whether to self-disclose to the government before close is one of the most consequential decisions in the transaction. Self-disclosure is a voluntary process through which a healthcare provider can report compliance issues to the OIG or CMS, calculate an estimated repayment obligation, and resolve the matter through a negotiated settlement that typically involves a reduced multiplier compared to what the government might seek in an enforcement action.

The OIG's Self-Disclosure Protocol and CMS's voluntary self-referral disclosure protocol are the two primary self-disclosure pathways for Stark and AKS issues. Both protocols require a disclosure of the nature and scope of the violation, a calculation of the financial impact, and payment of the settlement amount. In return, the disclosing party typically avoids criminal referral, civil monetary penalty exposure, and the prospect of a CIA.

In M&A contexts, the discovery of a self-disclosure-worthy issue creates a negotiation dynamic. The seller may prefer to disclose before close to quantify and limit liability. The buyer may prefer to see the disclosure resolved before agreeing to proceed. The purchase price adjustment, escrow, and indemnification structure will be affected by the existence and status of any pending or anticipated self-disclosure. Buyers should assess the issue with healthcare compliance counsel experienced in government self-disclosure programs before making decisions about deal structure.

Corporate Integrity Agreement: What Buyers Need to Know

CIA as a diligence finding: An existing CIA at the target is a material finding that affects deal structure, operations planning, and compliance infrastructure post-close. CIAs are public: buyers should search the OIG's public CIA database as part of preliminary diligence.

Obligations that survive close: A CIA entered into by the target entity (in a stock deal) or assumed by the buyer survives the transaction. The monitoring, reporting, and audit obligations under the CIA must be incorporated into the buyer's post-close compliance program.

Independent review organization audits: Most CIAs require periodic audits by an OIG-approved independent review organization (IRO) at the entity's expense. These audits cover claims accuracy, billing compliance, and compensation arrangement documentation. Buyers should factor CIA compliance costs into their financial model.

Exclusion screening requirements: CIAs typically require the entity to screen all employees, contractors, and vendors against the OIG's List of Excluded Individuals and Entities (LEIE) before hiring or engaging and on a periodic ongoing basis. This requirement extends to the acquired entity's operations post-close.

Post-Close Integration Concerns: Compensation Realignment

Even where a healthcare acquisition closes without identified Stark or AKS violations, post-close integration creates a new set of compliance considerations. The acquired physicians will be entering into new compensation arrangements with the buyer, and those new arrangements must be independently structured to satisfy applicable Stark exceptions and AKS safe harbors from the effective date of the new arrangements.

Post-close compensation realignment is the process of transitioning acquired physicians from their pre-close compensation structures into the acquirer's compensation framework. This transition must be handled carefully because it involves negotiating new employment or service agreements with physicians who are now aware that the buyer has an interest in their referral patterns. The existence of that economic alignment creates a context in which even legitimately structured compensation arrangements may receive increased scrutiny.

Common post-close integration issues for buyers include: ensuring that all acquired physicians sign written employment or independent contractor agreements that comply with the applicable Stark exception before the closing; obtaining independent FMV opinions for post-close compensation that reflect current market conditions rather than the pre-close structure; eliminating any compensation components that track referral volume or that cannot be justified on commercial reasonableness grounds; and integrating the acquired practice into the buyer's existing compliance program, including exclusion screening, training, and audit functions.

Representations and Warranties Tailored to Fraud and Abuse Risk

The representations and warranties section of a healthcare purchase agreement is where the parties allocate the risk of pre-close compliance failures. Well-drafted healthcare reps go significantly beyond the generic "compliance with law" representation that appears in most commercial M&A agreements. Buyers should work with counsel to tailor the fraud and abuse reps to the specific risk profile of the target practice.

Core Stark and AKS representations should cover: that the practice has complied in all material respects with Stark Law and the Anti-Kickback Statute throughout the lookback period; that all physician compensation arrangements are documented in written agreements, are at fair market value, and do not take into account the volume or value of referrals; that no compensation arrangement has been entered into or modified within the lookback period in a manner that correlates with referral patterns; and that the practice has not received any government inquiry, civil investigative demand, subpoena, or other request for information relating to fraud or abuse compliance.

Healthcare Fraud and Abuse Rep Checklist

✓Material compliance with Stark Law and Anti-Kickback Statute throughout the applicable lookback period
✓All physician compensation arrangements documented in written, signed agreements that meet applicable Stark exceptions and AKS safe harbors (or, for arrangements not meeting a safe harbor, no intent to induce referrals)
✓Compensation at fair market value and not determined by referral volume or value
✓No officer, director, employee, contractor, or agent is excluded from Medicare, Medicaid, or any federal healthcare program
✓No pending or threatened government investigation, audit, civil investigative demand, or subpoena relating to billing, referrals, or fraud and abuse
✓No existing CIA, deferred prosecution agreement, settlement agreement, or other compliance obligation with any government agency
✓No overpayment obligations known and not reported to CMS or MAC
✓Practice has not voluntarily disclosed any compliance issue to OIG or CMS that remains pending

The survival period for fraud and abuse representations should reflect the government's enforcement lookback period, which can extend six years or longer for False Claims Act matters. Healthcare M&A agreements often include extended survival periods and specific indemnification carve-outs for Stark, AKS, and FCA matters that survive beyond the general rep and warranty basket. The indemnification structure for healthcare fraud and abuse reps is addressed in more detail in the indemnification provisions guide.

Buyers evaluating deal structure for healthcare acquisitions should also review the asset purchase versus stock purchase guide for how structure affects liability allocation for pre-close Stark and AKS exposure. The MSO healthcare guide covers the management services organization structure frequently used in healthcare acquisitions where direct physician employment raises regulatory concerns.

Acquiring a Physician Practice and Need Stark and AKS Diligence?

Acquisition Stars works with healthcare buyers on physician practice and healthcare entity acquisitions, including Stark and Anti-Kickback diligence, compensation arrangement review, and post-close compliance structuring. Alex Lubyansky handles each engagement directly. Submit your transaction details to begin the engagement assessment process.

Request Engagement Assessment

Frequently Asked Questions

What is Stark Law?

Stark Law prohibits a physician from referring Medicare or Medicaid patients for designated health services to an entity with which the physician or an immediate family member has a financial relationship, unless a specific statutory or regulatory exception applies. Stark is strict liability: intent is not an element, and a violation is triggered by the existence of a non-excepted financial relationship regardless of whether it influenced the referral. Violations can result in claim non-payment, repayment obligations, civil monetary penalties, and exclusion from federal healthcare programs. This is a summary for educational purposes. Structure analysis in a transaction requires qualified healthcare counsel.

How is Stark different from Anti-Kickback?

Stark is civil and strict liability; the Anti-Kickback Statute is criminal and requires knowing and willful conduct. Stark applies specifically to physicians and designated health services under Medicare and Medicaid; AKS applies to any provider or supplier and covers all federal healthcare programs. Stark compliance requires fitting within a specific exception; AKS compliance where a safe harbor is not met is evaluated under an intent standard. Both statutes are commonly analyzed together in healthcare M&A diligence because conduct that implicates one often implicates the other, but the analyses are conducted separately using different legal frameworks.

Does Stark apply to private-pay only practices?

Stark Law applies only to Medicare and Medicaid billing. A practice with no Medicare or Medicaid patients is not subject to Stark's referral prohibition. In practice, very few physician practices operate entirely outside Medicare and Medicaid. Buyers should confirm whether the target has any Medicare or Medicaid billing before concluding Stark does not apply. Where even limited federal billing exists, the Stark analysis covers all financial relationships relevant to the practice's designated health services.

What is an FMV compensation opinion?

An FMV compensation opinion is an independent assessment by a qualified healthcare valuation expert of the fair market value of physician services or a physician financial arrangement. FMV opinions are used to document that compensation arrangements satisfy the fair market value requirement of applicable Stark exceptions and AKS safe harbors. In healthcare M&A, FMV opinions are relevant for both pre-close diligence and post-close compensation structuring. A credible FMV opinion is obtained from an independent valuation firm that specializes in physician compensation and is not determined by the volume or value of referrals between the parties.

What is the isolated transaction safe harbor?

The isolated transaction safe harbor under AKS protects certain one-time arm's length transactions, such as the sale of a physician practice, from AKS scrutiny. The transaction must be a single discrete event, the amount paid must be consistent with fair market value, and the consideration must not be determined by referral volume or value. The safe harbor covers the sale itself but not post-close employment or other ongoing arrangements, which must meet their own AKS safe harbor or exception independently. A parallel exception exists under Stark for isolated transactions. Safe harbor qualification analysis requires healthcare counsel review.

Can I inherit a Stark violation from the seller?

In a stock purchase, the buyer acquires the legal entity with its historical liabilities, including pre-close Stark and AKS compliance failures and any associated repayment obligations or government exposure. In an asset purchase, the buyer generally does not assume the seller's pre-close regulatory liabilities unless expressly assumed. Regardless of deal structure, buyers conduct Stark and AKS diligence to identify potential issues, negotiate representations and warranties covering compliance history, and structure indemnification to address pre-close violations discovered post-close.

What is a corporate integrity agreement?

A corporate integrity agreement (CIA) is a compliance agreement between a healthcare provider and the OIG, typically entered as part of resolving a healthcare fraud or abuse matter. CIAs impose specific ongoing compliance obligations, including independent audits, reporting requirements, and exclusion screening mandates. In healthcare M&A, a CIA at the target is a material diligence finding. CIA obligations survive a change of ownership in a stock acquisition and must be incorporated into the buyer's post-close compliance program. CIAs are publicly listed on the OIG's website and should be checked as part of preliminary diligence.

What reps should a buyer require on fraud and abuse?

Healthcare buyers should require representations covering: material compliance with Stark Law and AKS throughout the lookback period; all physician compensation arrangements documented in written agreements meeting applicable exceptions and safe harbors; compensation set at FMV without reference to referral volume; no excluded individuals as officers, employees, or contractors; no pending government investigations, audits, or civil investigative demands; no existing CIA or settlement agreements; and no known overpayment obligations not yet disclosed or repaid. Survival periods for these reps should reflect the government's extended enforcement lookback. Scope and structure of healthcare fraud and abuse reps require counsel with healthcare M&A experience. This summary is educational only.

Complete the Healthcare M&A Framework

Stark and AKS compliance is one layer of the healthcare M&A legal framework. Review the related guides for the complete picture.

Healthcare Practice Acquisition Guide: Complete Overview HIPAA Compliance in Healthcare M&A: BAAs, Notice, and PHI Transfer MSO Healthcare Guide Florida Healthcare M&A Regulatory Guide M&A Due Diligence Guide Indemnification Provisions in M&A Asset Purchase vs Stock Purchase M&A Deal Structures